Original Publication Date: 1 February, 2015
Publication / Source: Lung Cancer Management
Authors: Jyoti Malhotra, Denise Odea & Jorge E Gomez
Approximately 200,000 people will develop lung cancer in the USA this year. Roughly 85% of those will die of their disease. Standard chemotherapeutic agents have modestly prolonged survival in this population. The discovery of activating mutations, and their inhibitors has had a more significant impact, but this is limited to the small percentage of the population that harbor the currently known mutations with approved therapeutics.